Form 4: Candel Therapeutics CFO Charles Schoch Sells 5,000 Shares Under 10b5-1 Plan

Charles Schoch, Interim CFO of Candel Therapeutics, sold 5,000 shares of common stock at an average price of $8.8338 on March 17, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• On March 17, 2025, Charles Schoch, the Interim Chief Financial Officer of Candel Therapeutics, sold 5,000 shares of the company's common stock.
• The sale was executed at a weighted average price of $8.8338 per share.
• The transactions occurred within a price range of $8.74 to $8.98.
• This sale was conducted under a pre-arranged 10b5-1 trading plan adopted on November 15, 2024.
• Following the transaction, Schoch directly owns 38,038 shares of Candel Therapeutics.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a routine sale under a pre-arranged trading plan and doesn't necessarily indicate a positive or negative outlook for the company.

Industry Context

Insider sales are a common occurrence, and the use of a 10b5-1 trading plan suggests the sale was pre-planned and not based on any specific non-public information. Investors often monitor insider transactions for signals about a company's prospects, but sales under 10b5-1 plans are generally viewed as less informative.

Comparison to Industry Standards

• Comparing this transaction to similar insider sales in the biotech industry, the size of the sale (5,000 shares) is relatively small.
• Other biotech companies such as Amgen and Gilead Sciences often see much larger insider transactions, but these are typically by CEOs or board members.
• The use of a 10b5-1 plan is a standard practice to avoid accusations of insider trading, aligning with industry best practices.

Stakeholder Impact

• The sale of shares by an executive could be perceived negatively by some shareholders, but the existence of a 10b5-1 plan mitigates this concern.
• The impact on employees, customers, suppliers, and creditors is likely to be minimal.

Key Dates

Keywords

Candel Therapeutics, Charles Schoch, Form 4, Insider Trading, 10b5-1 Plan, Stock Sale, CADL, Interim CFO